Omega Therapeutics

Omega Therapeutics ™ is a privately-held, development-stage biotechnology company pioneering the field of epigenomic programming to precisely regulate and control the human genome to treat and cure disease. Omega’s breakthrough science has enabled it to tap into nature’s universal operating system that epigenetically controls the human genome, to target the most fundamental genomic processes which fuel cellular growth, differentiation, and gene expression. Omega Therapeutics was founded by Flagship Pioneering in 2017 and currently has eight programs in various stages of preclinical development. The Company is strategically pursuing specific disease targets that have not been successfully addressed through conventional modalities, including certain oncology indications, liver disease, serious inflammatory conditions, and acute respiratory distress syndrome (ARDS), among others. Omega’s mission is to transform medicine and deliver the therapies of tomorrow.